AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.61% | 14.24% | 10.10% | 2.34% | -8.07% |
| Total Depreciation and Amortization | -3.74% | -52.39% | -55.66% | -96.96% | -44.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.09% | 317.38% | 276.27% | 2,579.41% | 78.03% |
| Change in Net Operating Assets | -880.52% | -915.17% | -173.55% | 75.66% | 110.72% |
| Cash from Operations | -17.44% | -95.48% | -20.95% | 12.99% | 11.54% |
| Capital Expenditure | 57.46% | 44.57% | 45.44% | 37.10% | 26.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.44% | -44.80% | -34.68% | -30.10% | -40.54% |
| Cash from Investing | 530.51% | -44.95% | -27.72% | -21.29% | -65.42% |
| Total Debt Issued | 136.38% | 17.31% | 33.93% | -16.44% | -56.15% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 213.07% | -634.56% | -448.15% | 403.39% | 402.30% |
| Cash from Financing | 153.71% | -3.80% | 10.28% | 13.86% | -37.76% |
| Foreign Exchange rate Adjustments | -63.35% | 137.64% | 141.92% | -321.44% | 46.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 148.86% | -331.85% | -223.30% | 5.02% | -77.75% |